Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+
'I was relieved to learn about Guardant's Shield blood test because it's a more pleasant and convenient way to get screened, especially for those who've been hesitating.'
Known for iconic roles in Varsity Blues, Rules of Attraction and Don't Trust the B in Apartment 23, Van Der Beek has created many memorable characters in his 20+-year TV and film career, both on screen and as a producer, director and writer. Van Der Beek went public with his CRC diagnosis in November 2024 to encourage others to take control of their health. Today marks the first time he is speaking out about the critical importance of staying up to date with CRC screening guidelines.
'I was 46 years old, in great physical shape, and had no idea I was living with stage 3 colorectal cancer. It's the second most deadly cancer, but the most curable when caught in its early stages, making screening crucial,' said Van Der Beek. 'I was relieved to learn about Guardant's Shield blood test because it's a more pleasant and convenient way to get screened, especially for those who've been hesitating. I've learned a lot on my cancer journey, but I wouldn't wish this on anyone. Simply put, getting screened can save your life. If you're 45 or older, make sure you talk to your doctor about screening guidelines and your options.'
CRC is a significant health concern with over 50,000 Americans dying from the disease each year, making it the second most deadly cancer in the U.S. Early detection is crucial, as the five-year survival rate is over 90% when CRC is caught in its early stages, but plummets to 13% in late stages when symptoms usually appear. Despite these odds, more than 50 million people – one in three American adults age 45 and over – avoid screening in part because traditional methods are viewed as unpleasant or inconvenient.
'We are grateful to James for the work he has done to raise awareness with his personal story that shows the importance of screening and early detection,' said AmirAli Talasaz, Guardant Health co-CEO. 'Our goal is to ensure that everyone who should be screened for colorectal cancer gets screened – and the Shield blood test is a major step forward in making screening more convenient and accessible across the country. We are committed to saving lives through early detection and – with James' help – we hope more Americans are encouraged to take this critical step.'
'In my primary care practice, I'm on the frontlines of colorectal cancer and screenings are one of the best tools we have, helping us to catch and treat colorectal cancer at early stages,' said Dr. Angel Lazo, an internal medicine physician in New Jersey. 'In my practice, it can be difficult for patients to screen with traditional methods. Adding the option of Shield has made it much more convenient and expanded screening to more people, giving peace of mind to them – and to me as their doctor.'
Shield is the first blood test approved by the U.S. Food and Drug Administration as a primary screening option for CRC. It is intended for adults age 45 and older at average risk for the disease and can be ordered by any prescribing healthcare provider. With Shield, individuals can undergo screening with a simple blood draw and results are typically available within two weeks. Recently, the National Comprehensive Cancer Network included the Shield blood test in its updated CRC screening guidelines, paving the way for improved patient access and additional major clinical guideline inclusions.
For more information about the Shield blood test, visit www.ShieldCancerScreen.com.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients
Astria Therapeutics Inc. (NASDAQ:ATXS) is one of the stocks under $10 to buy now. Earlier on June 13, Astria Therapeutics announced positive initial results from the ALPHA-SOLAR long-term open-label trial of navenibart (STAR-0215) in hereditary angioedema/HAE patients. These findings were presented at the European Academy of Allergy and Clinical Immunology/EAACI Annual Congress. The trial showed an overall reduction in the monthly HAE attack rate, with a 92% mean and 97% median reduction. These results support the potential for every three-month and every six-month dosing regimens for navenibart, as well as its favorable safety and tolerability profile. These initial results from ALPHA-SOLAR are consistent with the 'best-in-class' profile observed in the earlier ALPHA-STAR Phase 1b/2 trial. A closeup of pills in a pharmacy, representing the high quality medications of the company. The ALPHA-SOLAR trial is a long-term, open-label study designed to assess the safety and efficacy of navenibart in adults with HAE Type 1 or 2. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial opted to enroll in ALPHA-SOLAR. Patients from ALPHA-STAR Cohorts 1 and 2 joined Arm A, while Cohort 3 patients joined Arm B. Astria Therapeutics Inc. (NASDAQ:ATXS) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for allergic and immunological diseases in the US. While we acknowledge the potential of ATXS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Childhood vaccine exemption rates hit a record high, CDC data shows
The percentage of kids who didn't get their recommended childhood vaccines rose again last school year, continuing the post-pandemic trend of Americans opting out of vaccinations. During the 2024-25 school year, 4.1% of kindergartners — about 138,000 kids — had a vaccine exemption, surpassing the previous record high of 3.7% during the prior school year. Nearly all exemptions are listed as nonmedical, meaning the kids aren't getting vaccines for religious or other personal reasons. The data, reported Thursday by the Centers for Disease Control and Prevention, comes as 2025 has logged the highest number of measles cases in 33 years: 1,333 cases in 39 states. Dr. Richard Besser, president of the Robert Wood Johnson Foundation and former acting director of the CDC, said he expects the rate of vaccination exemptions to continue to rise as long as Robert F. Kennedy Jr. — a long-time anti-vaccine activist — is health and human services secretary. 'While these numbers are bad, they don't even begin to reflect the impact that Secretary Kennedy will have on future exemptions,' Besser said. 'No one has done more to instill fear and distrust of vaccines.' HHS spokesman Andrew Nixon said in an email, 'That couldn't be further from the truth.' 'Vaccination remains the most effective way to protect children from serious diseases like measles and whooping cough, which can lead to hospitalization and long-term health complications,' Nixon said, adding that a family's decision to vaccinate is 'a personal one.' Approximately 286,000 kindergartners last school year had no documentation that they'd ever had the measles-mumps-rubella vaccine, the CDC said. Those children were toddlers when the pandemic hit in 2020. The MMR vaccine is given in two doses beginning at age 1. Just 92.5% of kids had their MMR and polio shots last year, and 92.1% had been vaccinated against tetanus and whooping cough. Both percentages are decreases from the year before. 'A drop in coverage like that can make a huge difference for keeping a disease like measles at bay,' said Josh Michaud, an associate director within the Global Health Policy program at KFF, a nonpartisan health policy organization. 'Lower measles vaccination rates are a key driver for outbreaks like the ones we're seeing across many states this year.' Measles is one of the most contagious viruses on Earth. Generally, 95% of the community must be vaccinated against it to prevent outbreaks. While states have different vaccination requirements for attending public and most private schools, they generally include MMR, poliovirus and chickenpox vaccines, as well as DTaP, which covers diphtheria, tetanus and acellular pertussis (also called whooping cough). This article was originally published on Solve the daily Crossword
USA Today
6 hours ago
- USA Today
How many people are affected by Lyme disease? Here's what to know
Justin Timberlake recently shared his Lyme disease diagnosis on social media, calling the experience "relentlessly debilitating." "If you've experienced this disease or know someone who has — then you're aware: living with this can be relentlessly debilitating, both mentally and physically," he wrote. Timberlake shed light on a disease that impacts thousands of Americans every year. Over 89,000 cases of Lyme disease were reported to the Centers for Disease Control and Prevention by state health departments in 2023 – the most recent year of data available. According to the CDC, other estimates found that the number of those diagnosed and treated for the disease could be as much as 476,000 annually. Globally, an estimated 14% of the world's population has been diagnosed with the disease, according to Project Lyme, an advocacy organization working to eradicate the epidemic of tick-borne diseases. The CDC said Lyme is the most common disease transmitted through tick bites. Here's what to know about the tick-borne illness: Where are ticks found? Maps show where the disease-carrying parasites live How to spot a Lyme disease-carrying tick The blacklegged tick and Western blacklegged tick can spread Lyme disease, which can lead to a wide range of health problems. In high-risk areas, an estimated 10% to 50% of blacklegged ticks carry the bacteria that cause Lyme disease. These high-risk areas include: Hallmark symptoms of Lyme disease in the acute stage include a 'bullseye' rash (erythema migrans), fever, chills, fatigue and muscle and joint aches. Without treatment, Lyme disease can progress to include neurological, heart and joint problems. Do you know the signs of a tick bite? What to look for How many people have Lyme disease? With climate change raising temperatures, tick populations have expanded into new regions and put more people in contact with ticks and their illness-causing bacteria. Annual cases are expected to continue to climb. Between 2022 and 2023, Lyme disease cases increased 43%. What is Lyme disease? Justin Timberlake shares 'debilitating' diagnosis How to stay safe from tick bites The CDC and other public health authorities recommend the following to keep you and your family safe from ticks:
